Braftovi (encorafenib) — CareFirst (Caremark)
BRAF V600 mutation-positive glioma
Initial criteria
- Diagnosis of central nervous system tumor (glioma, meningioma, or astrocytoma) with documented BRAF V600 mutation (e.g., V600E or V600K) confirmed by FDA-approved or validated test
Reauthorization criteria
- No evidence of disease progression or unacceptable toxicity while on current regimen
Approval duration
12 months